Integra Lifesciences Holdings Corp (NASDAQ:IART) currently has a daily average trading volume of 718.69K but it saw 863502 shares traded in last market. With a market cap of 1.27B USD, the company’s current market price of $16.39 came falling about -5.53 while comparing to the previous closing price of $17.35. In past 52 weeks, the stock remained buoying in the range of price level as high as $32.66 and as low as $14.45. In the recent trading on the day, stock has struck highest price mark of $16.37 while lowest mark touched by it was $17.205.
Taking a look at 20-day trading activity of Integra Lifesciences Holdings Corp (IART) gives us an average price of $17.41, while its current price level is -49.82% below from 52-week high level whereas it is 13.43% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.46 while that of 200 days or SMA-200 reads an average of $21.99. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.39% during that period while stretching the period over a month that increases to 6.94%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.98 which implies that the stock is in neutral territory.
Over the week, IART’s stock price is moving 0.80% up while it is -25.47% when we observe its performance for the past one month. Year-to-date it is -27.73% down and over the past year, the stock is showing a downside performance of -42.17%.
The company is expected to be releasing its next quarterly report on 2025-Feb-24, for which analysts forecasted an EPS of 0.43 while estimate for next year EPS is 2.46. In next quarter, company is expected to be making quarterly sales of $417.04M as analysts are expecting the sales for current fiscal year at $1.68B and seeing the company making $1.75B in sales next year. Moreover, analysts are in estimates of $381.17M for current-quarter revenue.
Currently, Integra Lifesciences Holdings Corp’s total number of outstanding shares is 77.17M with 14.28% of that held by the insiders while 93.22% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -0.24% and return on equity (ROE) at -0.44%. It has a 6.03 of forward P/E ratio. Stock’s beta reads 1.27. Stock has a price to book (P/B) ratio of 0.82 while price to sale or P/S ratio amounts to 0.79. Its return on asset (ROA) is -0.18% on average.
